NASDAQ:CNAT - Conatus Pharmaceuticals Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $1.21 +0.01 (+0.83 %) (As of 03/26/2019 04:00 PM ET)Previous Close$1.20Today's Range$1.1434 - $1.2452-Week Range$1.14 - $6.74Volume1.07 million shsAverage Volume878,094 shsMarket Capitalization$36.62 millionP/E Ratio-2.05Dividend YieldN/ABeta3.36 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Conatus Pharmaceuticals (NASDAQ:CNAT) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.5 Wall Street analysts have issued ratings and price targets for Conatus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.84, suggesting that the stock has a possible upside of 382.64%. The high price target for CNAT is $12.00 and the low price target for CNAT is $1.50. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: HoldBuyBuyBuyConsensus Rating Score: 2.202.802.803.00Ratings Breakdown: 0 Sell Rating(s)4 Hold Rating(s)1 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)1 Hold Rating(s)4 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)1 Hold Rating(s)4 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)0 Hold Rating(s)5 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $5.84$10.25$11.1150$12.4983Price Target Upside: 382.64% upside404.93% upside414.58% upside213.24% upsideConatus Pharmaceuticals (NASDAQ:CNAT) Consensus Price Target History Conatus Pharmaceuticals (NASDAQ:CNAT) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails3/26/2019Roth CapitalReiterated RatingBuy ➝ Neutral$1.70Medium3/22/2019HC WainwrightDowngradeBuy ➝ Neutral$8.00 ➝ $1.50High3/22/2019SunTrust BanksDowngradeBuy ➝ HoldHigh12/6/2018Stifel NicolausDowngradeBuy ➝ Hold$4.00High12/6/2018OppenheimerSet Price TargetBuy$14.00 ➝ $10.00High1/24/2018S&P Equity ResearchBoost Price Target$5.02 ➝ $5.69High10/6/2017Seaport Global SecuritiesReiterated RatingBuy$16.00N/A5/15/2017AegisReiterated RatingBuy$11.00N/A(Data available from 3/26/2017 forward) This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: What is the Coverage Ratio?